(Reuters) - Pfizer Inc said a U.S. health advisory panel voted against its drug to treat a rare neurodegenerative disease as the data did not show enough evidence of efficacy.
(Reuters) - Pfizer Inc said a U.S. health advisory panel voted against its drug to treat a rare neurodegenerative disease as the data did not show enough evidence of efficacy.
NEW YORK (Reuters) - Another showdown between Republicans in Congress and President Barack Obama over debt could be in the making, and some investors are already taking steps to prepare for it.
LOS ANGELES (Reuters) - Pharmaceutical companies, which were spared some of the more sweeping regulations in President Barack Obama's healthcare overhaul, could come under more pressure if the U.S. Supreme Court strikes down part or all of the 2010 law.
Wednesday, 23 May 2012 | Source: The Associated Press
Drugmaker Pfizer Inc. said Wednesday that David Simmons, the president and general manager of its emerging markets and established products divisions, is leaving the company to become president and CEO of Pharmaceutical Product Development Inc.
WASHINGTON (Reuters) - Drug reviewers on Tuesday recommended rejecting a Pfizer Inc drug because the data did not prove it worked well in treating a rare neurodegenerative disease.
The SPDR Health Care Select Sector exchange-traded fund is less than a sneeze from its recent highs, and some bulls are looking for it to pop.... Read More
Few stock sectors are as reliable as drugs and health care, and astute investors know that companies such as Merck, Pfizer, and Abbott Laboratories have delivered healthy returns over the years... Read More
Activist investor Daniel Loeb continues to put the heat on Yahoo, Cisco earnings beat but stock falls as they warn on outlook, Facebook says its mobile growth is growing faster than its advertising platform can keep up.... Read More